Validation of the Late-Life Function and Disability Instrument in people with COPD

<bold>Introduction:</bold> Disability and loss of function in daily life tasks are important challenges for people with COPD, but its assessment lacks valid instruments. <bold>Aim:</bold> To investigate the validity of the Late-Life Function and Disability Instrument (LLFDI, originally developed for community-dwelling older adults) in COPD. <bold>Method:</bold> This patient-reported instrument assesses the frequency, limitation and difficulty of performing important life tasks and has 3 domains (disability-frequency, disability-limitation and function). Scores range from 0 (worst) to 100 (best). The construct validity was assessed in a large European cohort study, by 1) convergent validity: Spearman correlation with COPD-relevant constructs (exercise capacity, dyspnea severity, health status) and 2) known-groups validity: differences in LLFDI levels according to meaningful groups (disease severity, age and use of walking aid). <bold>Results:</bold> This study involved 605 participants (68±8 years old, 63% male, 54±20 FEV1 %pred.), reporting reduced participation and function in life tasks (median (Q1-Q3) disability-frequency 48 (44-50) points; disability-limitation 64 (58-71) points; function 58 (53-64) points). Most of the correlations were as hypothesized (89%, fig.1A). All 3 domains were able to differentiate for disease severity, age groups and use of walking aids (fig. 1B). <bold>Conclusion:</bold> The LLFDI is valid to use in COPD to assess disability and loss of function from a patient perspective. <fig><object-id>erj;64/suppl_68/PA618/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa618
Primary Topic
Health and Wellbeing Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Validation of the Late-Life Function and Disability Instrument in people with COPD

Emily Hume, Nicholas S Hopkinson, Dimitrios Megaritis, Thierry Troosters et al.
Health and Wellbeing Research
article

Validation of the Late-Life Function and Disability Instrument in people with COPD

Emily Hume, Nicholas S Hopkinson, Dimitrios Megaritis, Thierry Troosters, Astrid Blondeel, Lies Glorie, Nikolaos Chynkiamis, Joren Buekers, Judith García‐Aymerich, Anne‐Marie Kirsten, Anja Frei, Sara Buttery, Laura Delgado‐Ortiz, Marieke Wuyts, Sarah Koch, Milo A. Puhan, Heleen Demeyer, Elena Gimeno‐Santos, Henrik Watz, Carl-Philipp Jansen, Victoria Alcaraz-Serrano, I. I. Vogiatzis, Paulien Mellaerts, Alícia Josa Culleré
article en

Abstract

<bold>Introduction:</bold> Disability and loss of function in daily life tasks are important challenges for people with COPD, but its assessment lacks valid instruments. <bold>Aim:</bold> To investigate the validity of the Late-Life Function and Disability Instrument (LLFDI, originally developed for community-dwelling older adults) in COPD. <bold>Method:</bold> This patient-reported instrument assesses the frequency, limitation and difficulty of performing important life tasks and has 3 domains (disability-frequency, disability-limitation and function). Scores range from 0 (worst) to 100 (best). The construct validity was assessed in a large European cohort study, by 1) convergent validity: Spearman correlation with COPD-relevant constructs (exercise capacity, dyspnea severity, health status) and 2) known-groups validity: differences in LLFDI levels according to meaningful groups (disease severity, age and use of walking aid). <bold>Results:</bold> This study involved 605 participants (68±8 years old, 63% male, 54±20 FEV1 %pred.), reporting reduced participation and function in life tasks (median (Q1-Q3) disability-frequency 48 (44-50) points; disability-limitation 64 (58-71) points; function 58 (53-64) points). Most of the correlations were as hypothesized (89%, fig.1A). All 3 domains were able to differentiate for disease severity, age groups and use of walking aids (fig. 1B). <bold>Conclusion:</bold> The LLFDI is valid to use in COPD to assess disability and loss of function from a patient perspective. <fig><object-id>erj;64/suppl_68/PA618/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>

Prevention Institute (US), Robert Bosch Hospital (DE), Northumbria University (GB), Lung Institute (US), German Center for Lung Research (DE), LungenClinic Grosshansdorf (DE), Barcelona Institute for Global Health (ES), Sotiria General Hospital (GR), Imperial College London (GB), KU Leuven (BE)
Openalex Percentile: Top 65%
Health and Wellbeing Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.